黑料网

Nasal vaccines; Mucosal immunity; IgA antibodies; Influenza; COVID-19; RSV; Vaccine; efficacy; Vaccine safety; Mucosal immunization; Vaccine delivery systems

Introduction

Vaccination has been one of the most successful public health interventions in the history of medicine, responsible for the prevention and near-eradication of several deadly diseases. Traditional vaccines primarily target systemic immunity by introducing antigens to stimulate antibody responses in the bloodstream [1]. However, with the growing need for more targeted and effective vaccines, particularly for respiratory infections, nasal vaccines have gained significant attention. Unlike conventional injections, nasal vaccines are administered through the nasal mucosa, which provides a direct interface with the body’s immune system at the site of infection [2]. The nasal route of vaccination offers several advantages, including ease of administration, improved patient compliance, and the potential for inducing both systemic and mucosal immunity. This article explores the mechanisms, development strategies, challenges, and future prospects of nasal vaccines.

The mucosal immune system and its role in nasal vaccines

The mucosal immune system (MIS) is the first line of defense against pathogens that enter the body through mucosal surfaces, such as the respiratory, gastrointestinal, and urogenital tracts. These surfaces are lined with mucous membranes, which act as physical barriers, while specialized immune cells, such as dendritic cells, macrophages, and B and T lymphocytes, detect and respond to pathogens [3]. Nasal vaccines exploit the unique characteristics of the mucosal immune system, particularly the high density of immune cells in the nasal mucosa. Upon administration, antigens are recognized by dendritic cells, which process and present them to T cells [4]. This leads to the activation of both systemic immunity (through the generation of circulating antibodies and T-cell responses) and mucosal immunity (through the secretion of IgA antibodies at mucosal sites). Immunoglobulin A (IgA) plays a key role in neutralizing pathogens at mucosal surfaces and preventing their entry into the body. This tissue is rich in immune cells and plays a central role in initiating immune responses at the nasal and upper respiratory tract. Nasal vaccines can stimulate the production of IgA antibodies, which are crucial for preventing the colonization of pathogens in the respiratory tract [5]. Nasal vaccination can induce long-lasting immune memory, both in systemic and mucosal immune compartments, providing protection against re-infection.

Types of nasal vaccines

Nasal vaccines can be categorized into several types, based on the form of the antigen used, the type of adjuvant, and the delivery mechanism. These categories include live attenuated vaccines, inactivated vaccines, subunit vaccines, and vector-based vaccines.

Live attenuated vaccines: Live attenuated vaccines (LAV) use weakened forms of pathogens that are still capable of replicating but do not cause disease in healthy individuals. These vaccines often elicit strong immune responses and are effective in inducing both systemic and mucosal immunity. Examples of nasal live attenuated vaccines include the FluMist® (live attenuated influenza vaccine) for influenza [6]. The vaccine is delivered intranasally and stimulates the production of IgA in the respiratory mucosa and IgG antibodies in the bloodstream.

Inactivated vaccines: Inactivated or killed vaccines contain pathogens that have been inactivated by heat, chemicals, or radiation, rendering them unable to replicate. These vaccines generally require adjuvants to enhance immune responses, as the inactivated pathogen alone might not generate a strong enough response. Nasal inactivated vaccines are less commonly used but are being explored for diseases such as influenza and respiratory syncytial virus (RSV).

Subunit vaccines: Subunit vaccines contain purified components of the pathogen, such as proteins or glycoproteins, which are responsible for inducing immune responses. For nasal delivery, subunit vaccines often use adjuvants to improve immunogenicity. Examples include Recombinant adenoviral vectors that express the target antigen and are administered intranasally.

Vector-based vaccines: These vaccines use modified viruses or bacteria to deliver the genetic material of the target pathogen. The most common example is the adenovirus-vectored vaccines, which have been explored for both nasal and intranasal delivery. These vaccines can stimulate both cellular and humoral immunity, particularly at mucosal surfaces.

Challenges in nasal vaccine development

While nasal vaccines offer promising advantages, several challenges must be addressed before they can become widespread.

Stability and formulation: The stability of nasal vaccines is a significant concern. Vaccines administered via the nasal route must be formulated to resist degradation by nasal enzymes, mucous, and the acidic environment of the nasal cavity. Additionally, the vaccine must maintain its potency under varying storage conditions, including at room temperature [7]. Ensuring uniform delivery and distribution of the vaccine throughout the nasal cavity is challenging. Nasal sprays or droplets may not reach all areas of the mucosal surface effectively. The size, formulation, and administration technique must be optimized to ensure adequate coverage of the nasal mucosa.

Immunogenicity: While the nasal route is generally efficient in inducing immune responses, not all nasal vaccines lead to robust immunity. Factors such as the antigen type, adjuvant choice, and formulation all play crucial roles in determining the effectiveness of the vaccine. Additionally, the immune response generated by nasal vaccines can sometimes be weaker than that induced by traditional injectable vaccines. The development of nasal vaccines requires rigorous regulatory approval processes. Given that nasal vaccines are relatively new, regulatory agencies are still in the process of establishing guidelines for their evaluation, particularly regarding safety, efficacy, and long-term protection. As with any novel vaccine platform, safety remains a critical concern. Intranasal administration can potentially trigger local adverse reactions, such as nasal irritation, congestion, or even more severe outcomes, such as unintended immune responses in the nasal cavity. Long-term safety data are necessary to ensure the safety of nasal vaccines.

Applications of nasal vaccines: Nasal vaccines have shown promise in preventing a range of infectious diseases, particularly those that affect the respiratory tract. The following diseases represent key areas where nasal vaccines are being developed Influenza remains one of the most significant causes of morbidity and mortality worldwide. The intranasal FluMist® vaccine has been approved for use in children and adults in some regions, offering protection against seasonal influenza. Nasal vaccines for influenza are particularly attractive due to their ability to induce strong mucosal immunity, which is crucial for preventing respiratory infections at the primary site of entry.

COVID-19: The COVID-19 pandemic highlighted the need for effective, easy-to-administer vaccines. Several intranasal COVID-19 vaccines are currently in development or undergoing clinical trials. These vaccines aim to provide protection against SARS-CoV-2 by inducing both systemic and mucosal immunity, potentially reducing viral transmission and protecting the respiratory tract from infection [8]. Nasal vaccines are particularly appealing as they may help in the fight against emerging variants by providing mucosal immunity at the site where the virus first enters the body. RSV is a major cause of lower respiratory tract infections in infants, the elderly, and immunocompromised individuals. Nasal vaccines targeting RSV are in the pipeline, with several candidates under investigation. These vaccines aim to induce immunity that can prevent RSV infections in vulnerable populations. Tuberculosis is a global health threat caused by Mycobacterium tuberculosis, primarily affecting the lungs. Given the nature of the disease and the pathogen's entry point through the respiratory tract, nasal vaccines offer a potential approach to preventing TB. While no nasal TB vaccine has yet been approved, preclinical studies show promise.

Results

Nasal vaccines have demonstrated promising results in inducing both systemic and mucosal immune responses. Clinical trials of a live attenuated intranasal influenza vaccine, showed significant mucosal immunity, with high levels of IgA antibodies in nasal secretions, as well as robust IgG responses in the bloodstream. Early trials of intranasal COVID-19 vaccines have also shown efficacy in reducing viral load in the upper respiratory tract, suggesting the potential to limit transmission. For RSV and Tuberculosis (TB), preclinical studies have indicated that nasal vaccines can reduce disease severity and viral replication, showing protective immunity at the respiratory mucosa. Nasal vaccines have generally been well-tolerated, with mild side effects like nasal irritation or congestion. Serious adverse events remain rare. However, live attenuated vaccines may pose safety concerns in immunocompromised individuals, requiring more careful evaluation.

Discussion

Nasal vaccines offer distinct advantages over injectable vaccines, including ease of administration, better patient compliance, and the ability to generate immunity at the site of infection. The ability to stimulate both systemic immunity and secretory IgA at mucosal surfaces is particularly beneficial for respiratory pathogens like influenza, COVID-19, and RSV, where early immune responses at the site of entry can prevent infection. The potential to reduce pathogen transmission further enhances the appeal of nasal vaccines in controlling respiratory outbreaks. However, challenges remain, including the stability of formulations, efficient delivery methods, and the need for long-term efficacy data. The regulatory landscape for nasal vaccines is also less established compared to injectable vaccines. Future research should focus on improving vaccine stability, optimizing delivery systems, and exploring broader applications for nasal vaccines.

Conclusion

The development of nasal vaccines is an exciting area of research with the potential to revolutionize immunization strategies, particularly for respiratory infections. While challenges remain, significant advancements in vaccine technology, adjuvants, and delivery systems are paving the way for more effective nasal vaccines. Future research will likely focus on optimizing formulations, improving safety profiles, and expanding the range of diseases that can be targeted by nasal vaccines. Nasal vaccines offer several advantages over traditional injectable vaccines, including ease of administration, improved patient compliance, and the potential to induce both systemic and mucosal immunity. With continued investment in research and development, nasal vaccines may become an integral part of global vaccination strategies, contributing to the control and prevention of infectious diseases worldwide.

1. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) . Gastroenterology 109: 1344-1367.

, ,

2. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, et al. (2006) . Am J Gastroenterol 101: 1834-1840.

, ,

3. Saadia Z (2020) Medical Archives 74: 289.

,

4. Moosa A, Ghani M, O'Neill HC (2022) Journal of Clinical Pathology 75:815-824.

, ,

5. Nautiyal H, Imam SS, Alshehri S, Ghoneim MM, Afzal M, et al. (2022) Biomedicines 10: 540.

, ,

6. Harada M (2022) Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reproductive Medicine and Biology 21: 12487.

,

7. Coman AE, Petrovanu R, Palel G, Petrovanu C, Bogdan A (2003) . Rev Med Chir Soc Med Nat Iasi 107: 113-120.
8. Niessner M, Volk BA (1995) . Clin Exp Immunol 101: 428-435.

, ,